BioTuesdays

Category - Markets

HCW starts Corcept Therapeutics at buy; PT $18

H.C. Wainwright launched coverage of Corcept Therapeutics (NASDAQ:CORT) with a “buy” rating and $18 price target. The stock closed at $12.59 on Sept. 5. Corcept is focused on development and commercialization of...

Stereotaxis

Stereotaxis to uplist to NYSE American

The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on...

Tetraphase Pharmaceuticals

HCW cuts Tetraphase Pharma to neutral and removes PT

H.C. Wainwright downgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “neutral” from “buy” and removed its price target, citing an early debt payoff that substantially increases the company’s risk. The stock closed at...

Tracon Pharmaceuticals Logo

HCW starts TRACON Pharma at buy; PT $2

H.C. Wainwright launched coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $2 price target. The stock closed at 57 cents on Aug. 29. TRACON is developing targeted therapeutics for cancer...

Cerus

Stifel starts Cerus at buy; PT $7

Stifel initiated coverage of Cerus (NASDAQ:CERS) with a “buy” rating and $7 price target. The stock closed at $5.21 on Aug. 27. “Over time, we see significant potential upside as the company executes against its high...

Profound Medical Logo

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...